KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palvella Therapeutics (PVLA) Income from Continuing Operations (2016 - 2026)

Palvella Therapeutics has reported Income from Continuing Operations over the past 10 years, most recently at 11927000.0 for Q3 2022.

  • Quarterly Income from Continuing Operations rose 37.25% to 11927000.0 in Q3 2022 from the year-ago period, while the trailing twelve-month figure was 42590000.0 through Sep 2022, up 19.98% year-over-year, with the annual reading at 64000.0 for FY2025, N/A changed from the prior year.
  • Income from Continuing Operations was 11927000.0 for Q3 2022 at Palvella Therapeutics, up from 12198000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 203000.0 in Q2 2018 and troughed at 19008000.0 in Q3 2021.
  • The 5-year median for Income from Continuing Operations is 10348000.0 (2019), against an average of 8897000.0.
  • Year-over-year, Income from Continuing Operations soared 97.99% in 2018 and then tumbled 5692.12% in 2019.
  • A 5-year view of Income from Continuing Operations shows it stood at 11682000.0 in 2018, then skyrocketed by 93.4% to 771000.0 in 2019, then tumbled by 1508.69% to 12403000.0 in 2020, then grew by 11.27% to 11005000.0 in 2021, then decreased by 8.38% to 11927000.0 in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Income from Continuing Operations are 11927000.0 (Q3 2022), 12198000.0 (Q2 2022), and 7460000.0 (Q1 2022).